MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
Portfolio Pulse from Lara Goldstein
MindMed has published an independent report by former FDA officials supporting its clinical and regulatory plan for its proprietary LSD compound, MM-120. The report states that the ongoing Phase 2b trial is well-designed and essential, and that FCM Holdings' proposal to skip Phase 2 is unrealistic and risky.
May 25, 2023 | 6:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's MM-120 development strategy is supported by an independent report from former FDA officials, which may strengthen investor confidence in the company.
The independent report by former FDA officials validates MindMed's clinical and regulatory plan for MM-120, dismissing FCM Holdings' proposal to skip Phase 2. This support may increase investor confidence in MindMed's strategy and potentially have a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100